The UK and US have announced a key bilateral deal that will guarantee no levies on British drug exports being sold in the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the NHS. This commitment guarantees that tariffs on these vital exports will be held at nothing for a period of the next three years.
This agreement is in response to previous statements to significantly raise duties on patented pharmaceutical products, with figures mentioned up to 100%.
"This arrangement between the Britain strengthens the worldwide climate for innovative medicines and brings long-overdue equity to U.S.–U.K. drug exports," a statement noted.
Commercial Significance
Drugs represent one of the the United Kingdom's biggest export categories to the US, which is easily the primary destination for leading British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of last September, the UK sold drugs totaling over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This deal secures jobs, boosts investment and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The deal entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to raise total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage drug companies must return to the NHS to control costs will be limited at fifteen percent. Last year, refunds were more than twenty percent.
Industry Background
The deal follows a ongoing dispute between the sector and the ministers over medicine costs and regulatory access.
This friction were intensified by arguments that American consumers were paying significantly more for the same drugs than people in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been halted or cancelled, while major investments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the past decade.
